Tumor vessel co-option probed by single-cell analysis.
No Thumbnail Available
Identifiers
Date
2021
Authors
Teuwen, Laure-Anne
De Rooij, Laura P M H
Cuypers, Anne
Rohlenova, Katerina
Dumas, Sébastien J
García-Caballero, Melissa
Meta, Elda
Amersfoort, Jacob
Taverna, Federico
Becker, Lisa M
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent.
Description
MeSH Terms
Animals
Cell Line, Tumor
Endothelial Cells
Female
Kidney Neoplasms
Lung Neoplasms
Macrophages
Mice, Inbred BALB C
Myeloid Cells
Neoplasms
Pericytes
Single-Cell Analysis
Cell Line, Tumor
Endothelial Cells
Female
Kidney Neoplasms
Lung Neoplasms
Macrophages
Mice, Inbred BALB C
Myeloid Cells
Neoplasms
Pericytes
Single-Cell Analysis
DeCS Terms
CIE Terms
Keywords
anti-angiogenic therapy, cancer cells, endothelial cells, macrophages, metastasis, pericytes, resistance, single-cell RNA sequencing, tumor angiogenesis, tumor vessel co-option